TMO
Thermo Fisher Scientific Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Buy
+45/100
Last price
659.00
▼ 17.76 (2.62%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
677.76
Prev close
676.76
Day high
694.33
Day low
654.51
Volume
2.75M
Market cap
$242.77B
P/E (TTM)
36.42
52W range
435.27 – 694.33
Day trading desk
Gap from prior close
+0.15%
Prior close 676.76
VWAP
660.97
-0.30% from price
Relative volume
3.65×
Unusually busy
Session range
6.08%
654.51 – 694.33
Position in range
11%
Near session low
ATR (14D)
17.97
2.73% of price
Prior day high
676.76
PDH
Prior day low
648.04
PDL
Bid / ask spread
—
Quote not published
Session volume
7.56M
Avg 2.07M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.39%
-5.3%
1M
+6.97%
+5.8%
3M
+28.71%
+24.2%
6M
+34.13%
+15.9%
YTD
+13.31%
-0.9%
1Y
+20.85%
+4.4%
3Y
+29.72%
-52.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
11 more panels on TMO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-10.82K
Net selling
Buy transactions
20
92.48K shares
Sell transactions
12
103.30K shares
Net transactions
+32
Buys less sells
Sell : buy shares
1.1 : 1
Mixed
Insider-held shares
480.67K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 31, 26 | PETTITI GIANLUCA President |
CONVERSION | 3.73K | $1.16M | Direct |
| Aug 31, 26 | PETTITI GIANLUCA President |
SELL | 4.13K | $2.54M | Direct |
| Aug 24, 26 | CASPER MARC N Chief Executive Officer |
CONVERSION | 275 | $85.15K | Direct |
| Aug 24, 26 | CASPER MARC N Chief Executive Officer |
SELL | 275 | $172.44K | Direct |
| Aug 21, 26 | CASPER MARC N Chief Executive Officer |
CONVERSION | 20.00K | $6.19M | Direct |
| Aug 21, 26 | CASPER MARC N Chief Executive Officer |
SELL | 20.00K | $12.56M | Direct |
| Aug 19, 26 | BRITT LISA P Officer |
CONVERSION | 11.44K | $4.79M | Direct |
| Aug 19, 26 | BRITT LISA P Officer |
SELL | 11.44K | $7.01M | Direct |
| Aug 11, 26 | SHAFER MICHAEL D Officer |
CONVERSION | 25.50K | $9.45M | Direct |
| Aug 11, 26 | SHAFER MICHAEL D Officer |
SELL | 25.50K | $15.30M | Direct |
| Aug 7, 26 | HOLMES JOSEPH R. Officer |
CONVERSION | 420 | $130.04K | Direct |
| Aug 7, 26 | CASPER MARC N Chief Executive Officer |
CONVERSION | 275 | $85.15K | Direct |
| Aug 7, 26 | CASPER MARC N Chief Executive Officer |
SELL | 4.88K | $2.86M | |
| Aug 7, 26 | HOLMES JOSEPH R. Officer |
SELL | 420 | $245.62K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BOXER MICHAEL A |
General Counsel | 10.81K | Sale |
BRITT LISA P |
Officer | 14.78K | Conversion of Exercise of derivative security |
CASPER MARC N |
Chief Executive Officer | 140.22K | Conversion of Exercise of derivative security |
CHAI NELSON J |
Director | 15.32K | Stock Award(Grant) |
LAGARDE MICHEL |
Chief Operating Officer | 86.35K | Stock Award(Grant) |
LOWERY FREDERICK M. |
Officer | 17.13K | Stock Award(Grant) |
PETTITI GIANLUCA |
President | 23.22K | Conversion of Exercise of derivative security |
SHAFER MICHAEL D |
Officer | 20.99K | Conversion of Exercise of derivative security |
SPERLING SCOTT M |
Director | 69.48K | Stock Award(Grant) |
WILLIAMSON STEPHEN |
Chief Financial Officer | 46.09K | Stock Award(Grant) |
Fundamentals
Market cap$242.77B
Enterprise value$281.38B
Revenue (TTM)$46.34B
Gross profit$18.99B
EBITDA$11.74B
Net income$6.97B
EPS (TTM)$18.03
Free cash flow$6.24B
Total cash$4.06B
Total debt$42.55B
Book value / share$142.47
Shares outstanding369.75M
Float368.82M
Short % of float1.36%
Dividend yield0.28%
Beta (5Y)0.88
Valuation & profitability ratios
Trailing P/E36.42
Forward P/E23.82
PEG ratio2.02
Price / sales—
Price / book4.61
EV / revenue6.07
EV / EBITDA23.97
Gross margin40.99%
Operating margin18.75%
Profit margin15.04%
Return on equity13.51%
Return on assets5.13%
Debt / equity80.58
Current ratio1.55
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $44.56B | $42.88B | $42.86B | $44.91B | +3.9% |
| Operating revenue | $44.56B | $42.88B | $42.86B | $44.91B | +3.9% |
| Cost of revenue | $26.32B | $25.18B | $25.76B | $25.94B | +4.5% |
| Gross profit | $18.24B | $17.70B | $17.10B | $18.97B | +3.0% |
| Research & development | $1.40B | $1.39B | $1.34B | $1.47B | +0.5% |
| Selling, general & admin | $8.73B | $8.60B | $8.45B | $8.99B | +1.6% |
| Total operating expense | $10.13B | $9.98B | $9.78B | $10.46B | +1.4% |
| Operating income | $8.11B | $7.72B | $7.32B | $8.51B | +5.1% |
| Net interest income | -$426.00M | -$312.00M | -$496.00M | -$454.00M | -36.5% |
| Pre-tax income | $7.31B | $7.04B | $6.30B | $7.83B | +3.9% |
| Tax provision | $547.00M | $657.00M | $284.00M | $703.00M | -16.7% |
| Net income | $6.70B | $6.33B | $6.00B | $6.95B | +5.8% |
| Net income to common | $6.70B | $6.33B | $6.00B | $6.95B | +5.8% |
| Basic EPS | 17.77 | 16.58 | 15.52 | 17.75 | +7.2% |
| Diluted EPS | 17.74 | 16.53 | 15.45 | 17.63 | +7.3% |
| EBIT | $8.73B | $8.43B | $7.67B | $8.56B | +3.6% |
| EBITDA | $11.51B | $11.54B | $11.08B | $11.94B | -0.2% |
| Basic shares | 377.00M | 382.00M | 386.00M | 392.00M | -1.3% |
| Diluted shares | 378.00M | 383.00M | 388.00M | 394.00M | -1.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $9.85B | $4.01B | $8.08B | $8.52B | +145.7% |
| Cash & short-term investments | $10.11B | $5.57B | $8.08B | $8.52B | +81.4% |
| Accounts receivable | $8.90B | $8.19B | $8.22B | $8.12B | +8.7% |
| Inventory | $5.42B | $4.98B | $5.09B | $5.63B | +9.0% |
| Total current assets | $28.71B | $22.14B | $24.59B | $25.23B | +29.7% |
| Property, plant & equipment | $10.56B | $9.31B | $9.45B | $9.28B | +13.5% |
| Goodwill & intangibles | $65.20B | $61.39B | $60.69B | $58.64B | +6.2% |
| Total assets | $110.34B | $97.32B | $98.73B | $97.15B | +13.4% |
| Total current liabilities | $15.19B | $13.33B | $14.01B | $17.01B | +13.9% |
| Current debt | $3.53B | $2.21B | $3.61B | $5.58B | +59.6% |
| Long-term debt | $35.85B | $29.06B | $31.31B | $28.91B | +23.4% |
| Total debt | $39.38B | $31.27B | $34.92B | $34.49B | +25.9% |
| Total liabilities | $56.81B | $47.65B | $51.88B | $53.01B | +19.2% |
| Retained earnings | $59.16B | $53.10B | $47.36B | $41.91B | +11.4% |
| Shareholder equity | $53.41B | $49.59B | $46.73B | $43.98B | +7.7% |
| Working capital | $13.52B | $8.80B | $10.58B | $8.22B | +53.5% |
| Net tangible assets | -$11.79B | -$11.80B | -$13.96B | -$14.66B | +0.1% |
| Shares issued | 445.16M | 443.84M | 442.19M | 440.67M | +0.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $6.72B | $6.34B | $5.96B | $6.96B | +6.0% |
| Depreciation & amortisation | $2.78B | $3.11B | $3.41B | $3.38B | -10.6% |
| Stock-based compensation | $310.00M | $301.00M | $278.00M | $307.00M | +3.0% |
| Change in working capital | -$1.77B | -$334.00M | -$495.00M | -$1.01B | -428.7% |
| Operating cash flow | $7.82B | $8.67B | $8.41B | $9.15B | -9.8% |
| Capital expenditure | -$1.52B | -$1.40B | -$1.48B | -$2.24B | -8.9% |
| Investing cash flow | -$4.05B | -$5.84B | -$5.14B | -$2.16B | +30.7% |
| Share buybacks | -$3.00B | -$4.00B | -$3.00B | -$3.00B | +25.0% |
| Dividends paid | -$636.00M | -$583.00M | -$523.00M | -$455.00M | -9.1% |
| Financing cash flow | $1.80B | -$6.79B | -$3.62B | -$2.81B | +126.5% |
| Free cash flow | $6.29B | $7.27B | $6.93B | $6.91B | -13.4% |
| End cash position | $9.88B | $4.04B | $8.10B | $8.54B | +144.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $11.99B | $11.01B | $12.21B | $11.12B | $10.85B | +9.0% |
| Operating revenue | $11.99B | $11.01B | $12.21B | $11.12B | $10.85B | +9.0% |
| Cost of revenue | $7.11B | $6.58B | $7.20B | $6.54B | $6.45B | +8.2% |
| Gross profit | $4.88B | $4.43B | $5.01B | $4.58B | $4.41B | +10.2% |
| Research & development | $364.00M | $336.00M | $356.00M | $346.00M | $352.00M | +8.3% |
| Selling, general & admin | $2.33B | $2.18B | $2.35B | $2.16B | $2.14B | +7.0% |
| Total operating expense | $2.70B | $2.52B | $2.71B | $2.51B | $2.49B | +7.2% |
| Operating income | $2.19B | $1.91B | $2.30B | $2.08B | $1.92B | +14.2% |
| Net interest income | -$194.00M | -$121.00M | -$107.00M | -$113.00M | -$107.00M | -60.3% |
| Pre-tax income | $1.92B | $1.73B | $2.15B | $1.83B | $1.71B | +11.0% |
| Tax provision | $167.00M | $70.00M | $153.00M | $207.00M | $92.00M | +138.6% |
| Net income | $1.74B | $1.65B | $1.96B | $1.62B | $1.62B | +5.1% |
| Net income to common | $1.74B | $1.65B | $1.96B | $1.62B | $1.62B | +5.1% |
| Basic EPS | 4.68 | 4.44 | 5.22 | 4.28 | 4.28 | +5.4% |
| Diluted EPS | 4.68 | 4.43 | 5.21 | 4.27 | 4.28 | +5.6% |
| EBIT | $2.33B | $2.09B | $2.52B | $2.17B | $2.11B | +11.4% |
| EBITDA | $3.14B | $2.82B | $3.25B | $2.83B | $2.80B | +11.3% |
| Basic shares | 371.00M | 372.00M | 376.00M | 378.00M | 378.00M | -0.3% |
| Diluted shares | 371.00M | 373.00M | 377.00M | 378.00M | 378.00M | -0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.06B | $3.25B | $9.85B | $1.98B | $4.58B | +24.9% |
| Cash & short-term investments | $4.06B | $3.26B | $10.11B | $3.55B | $6.39B | +24.8% |
| Accounts receivable | $9.45B | $9.20B | $8.90B | $8.91B | $8.59B | +2.7% |
| Inventory | $5.63B | $5.50B | $5.42B | $5.75B | $5.56B | +2.4% |
| Total current assets | $23.36B | $22.32B | $28.71B | $22.30B | $24.58B | +4.7% |
| Property, plant & equipment | $10.76B | $10.66B | $10.56B | $10.18B | $9.63B | +0.9% |
| Goodwill & intangibles | $73.44B | $74.33B | $65.20B | $65.53B | $62.40B | -1.2% |
| Total assets | $113.17B | $113.28B | $110.34B | $103.02B | $101.23B | -0.1% |
| Total current liabilities | $15.07B | $14.62B | $15.19B | $14.89B | $12.72B | +3.1% |
| Current debt | $3.37B | $3.09B | $3.53B | $3.82B | $2.21B | +9.0% |
| Long-term debt | $39.18B | $40.07B | $35.85B | $31.86B | $33.02B | -2.2% |
| Total debt | $42.55B | $43.16B | $39.38B | $35.68B | $35.23B | -1.4% |
| Total liabilities | $60.37B | $61.22B | $56.81B | $51.87B | $50.63B | -1.4% |
| Retained earnings | $62.19B | $60.63B | $59.16B | $57.35B | $55.90B | +2.6% |
| Shareholder equity | $52.68B | $51.93B | $53.41B | $51.02B | $50.51B | +1.4% |
| Working capital | $8.30B | $7.70B | $13.52B | $7.41B | $11.87B | +7.8% |
| Net tangible assets | -$20.76B | -$22.40B | -$11.79B | -$14.51B | -$11.89B | +7.3% |
| Shares issued | 369.75M | 445.47M | 445.16M | 444.64M | 444.37M | -17.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $1.74B | $1.66B | $1.97B | $1.62B | $1.62B | +5.1% |
| Depreciation & amortisation | $817.00M | $736.00M | $728.00M | $661.00M | $686.00M | +11.0% |
| Stock-based compensation | $82.00M | $83.00M | $84.00M | $70.00M | $81.00M | -1.2% |
| Change in working capital | -$425.00M | -$1.11B | $489.00M | -$104.00M | -$726.00M | +61.8% |
| Operating cash flow | $2.13B | $1.19B | $3.46B | $2.24B | $1.40B | +78.3% |
| Capital expenditure | -$450.00M | -$376.00M | -$465.00M | -$404.00M | -$294.00M | -19.7% |
| Investing cash flow | $164.00M | -$8.96B | $891.00M | -$4.12B | -$288.00M | +101.8% |
| Share buybacks | -$1.00B | -$3.00B | -$37.00M | -$963.00M | $0 | +66.7% |
| Dividends paid | -$175.00M | -$162.00M | -$162.00M | -$163.00M | -$162.00M | -8.0% |
| Financing cash flow | -$1.57B | $1.09B | $3.53B | -$632.00M | -$991.00M | -243.7% |
| Free cash flow | $1.68B | $816.00M | $2.99B | $1.83B | $1.10B | +105.3% |
| End cash position | $4.10B | $3.28B | $9.88B | $2.01B | $4.60B | +24.9% |
Options analytics
Put / call volume
0.69
Call-heavy session
Put / call open interest
1.77
Positioning, not flow
Max pain
650.00
-1.0% from spot
ATM implied vol
53.1%
Nearest strike to spot
Skew (10% OTM)
+30.9%
Puts bid over calls
Call volume
969
Contracts, this expiry
Put volume
672
Contracts, this expiry
Heaviest call OI
700.00
270 contracts
Heaviest put OI
540.00
1.44K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 5.71 | 6.03 | +5.6% |
| Mar 2026 | 5.24 | 5.44 | +3.8% |
| Dec 2025 | 6.45 | 6.57 | +1.9% |
| Sep 2025 | 5.50 | 5.79 | +5.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 6.40 | 21 | $11.95B | +7.4% |
| Next quarter | 7.26 | 19 | $12.91B | +5.7% |
| Current year | 25.13 | 26 | $47.87B | +7.4% |
| Next year | 27.56 | 27 | $50.33B | +5.1% |
Analyst targets & ownership
Mean target$665.16
High target$780.00
Low target$560.00
Implied upside0.93%
Analyst count25
ConsensusBUY
Strong buy / Buy4 / 19
Hold3
Sell / Strong sell0 / 1
Held by insiders0.13%
Held by institutions94.06%
Institutions holding3.55K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
669.26
-1.53% from price
SMA 20
652.09
+0.69% from price
SMA 50
621.56
+5.63% from price
SMA 100
557.91
+18.12% from price
SMA 200
543.61
+20.78% from price
EMA 12
661.47
-0.37% from price
EMA 26
646.62
+1.92% from price
EMA 50
620.54
+6.20% from price
RSI (14)
54.6
Neutral
MACD (12,26,9)
14.86
Hist -2.25
ATR (14)
17.97
2.74% of price
Realised vol 30D
26.5%
Annualised
Bollinger upper
701.24
20, 2σ
Bollinger lower
602.94
20, 2σ
50 / 200 cross
Golden
621.56 vs 543.61
Trend bias
Above 200
+20.78%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.54
Less volatile than market
Correlation to SPY
0.24
Largely independent
Realised vol 30D
26.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-31.5%
Peak to trough
Max drawdown 5Y
-41.5%
Peak to trough
ATR 14
17.97
2.74% of price
Beta (reported)
0.88
5Y monthly, from filing
Short interest
Shares short
5.02M
Prior 4.74M
Change vs prior
+5.8%
Shorts adding
% of float
1.36%
Normal
% of shares out
1.36%
Against total outstanding
Days to cover
2.9
Liquid
Float
368.82M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 3, 26 | CLSA | INITIATED | — | Outperform |
| Jul 27, 26 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| Jul 27, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Jul 24, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Jul 24, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jul 6, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Jun 11, 26 | Piper Sandler | INITIATED | — | Neutral |
| Jun 3, 26 | HSBC | DOWNGRADE | Buy | Hold |
| May 8, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Apr 24, 26 | Stifel | MAINTAINED | Buy | Buy |
| Apr 24, 26 | Baird | MAINTAINED | Outperform | Outperform |
| Apr 14, 26 | Barclays | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate$1.88 / yr
Forward yield0.28%
5-year avg yield0.25%
Payout ratio9.69%
Ex-dividend dateSep 15, 2026
Next pay dateOct 15, 2026
Last split3:2
Split dateJun 6, 1996
SEC filings
Periodic Financial Reports
10-Q · 2026-07-31
Corporate Changes & Voting Matters
8-K · 2026-07-23
Annual report of employee stock purchase
11-K · 2026-06-23
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-28
Corporate Changes & Voting Matters
8-K · 2026-05-26
Proxy Statements
DEFA14A · 2026-05-11
Periodic Financial Reports
10-Q · 2026-05-01
Corporate Changes & Voting Matters
8-K · 2026-04-23
Headlines
JPMorgan reveals stocks worth buying in October 2026
TheStreet · 7h ago
Thermo Fisher Scientific (TMO): Strong Q3 Guidance and Broadening Demand Support Multi-Year Outlook
Insider Monkey · 12h ago
Barclays Adjusts Thermo Fisher Scientific Price Target to $750 From $650, Maintains Overweight Rating
MT Newswires · 14h ago
Quantum BioPharma, Thermo Fisher Partner on Phase 2 Multiple Sclerosis Trial
MT Newswires · 15h ago
Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
GlobeNewswire · 16h ago
Biopharma's Leapfrog Moment: The Launch of the Digital CMC Consortium
PR Newswire · 16h ago
EXCLUSIVE: Thermo Fisher To Support Quantum Biopharma in Progressive Multiple Sclerosis Drug Trial
Benzinga · 16h ago
Thermo Fisher Scientific Showcases New Solutions and Expanded Capabilities to Accelerate Drug Development at CPHI Milan 2026
Business Wire · 20h ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.